Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry
Retrieved on:
Tuesday, May 17, 2022
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Senior, GSK, Inflammation, Janssen, Doctor of Philosophy, University of Illinois at Chicago College of Dentistry, Disease, Wyeth, Patient, Science, Therapy, Imperial College London, Molecular Cancer Research, Central nervous system disease, Duke University Hospital, CNS, Partnership, Neurodegeneration, UCB, RNA, HIV disease progression rates, University, REMIX, Protein, EZH2, Acquisition, LLC, Drug discovery, Quantum, Cancer, Medicinal chemistry, AstraZeneca, Lists of diseases, Pharmaceutical industry, Fine chemical, Monte Civetta, Biology, Chemistry
Its an exciting time for the company as we move toward the clinic, and Jesse and Sue bring tremendous translational drug development experience across multiple therapeutic areas.
Key Points:
- Its an exciting time for the company as we move toward the clinic, and Jesse and Sue bring tremendous translational drug development experience across multiple therapeutic areas.
- They, like others on the Civetta leadership team, have firsthand experience leading programs into the clinic and beyond.
- Jesse Smith, Ph.D., has over 20 years of experience advancing novel science, drug discovery, and therapeutics across the biotech and pharma industry.
- Civetta is a biotechnology company focused on the development of therapies that target beta-propeller domains to treat cancer and other diseases.